| Field | Specification |
|---|---|
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C21H17N3O2S |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
iCRT 14 is a potent inhibitor of β-catenin-responsive transcription (CRT), with an IC50 of 40.3 nM against Wnt-responsive STF16 luciferase. It is supplied as a light yellow to yellow solid (C21H17N3O2S, MW 375.44) at 99.72% purity.
Physical & Chemical Properties
| CAS Number | 677331-12-3 |
|---|---|
| Molecular Formula | C21H17N3O2S |
| Molecular Weight | 375.44 g/mol |
| Purity | 99.72% |
| Appearance | Solid |
| Color | Light yellow to yellow |
| SMILES | O=C(S/1)N(C2=CC=CC=C2)C(C1=C\C3=C(C)N(C(C)=C3)C4=CN=CC=C4)=O |
| Signaling Pathway | Stem Cell/Wnt |
| Solubility | In Vitro: DMSO: ≥ 29 mg/mL (77.24 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) * "≥" means soluble, but saturation unknown. |
| Storage | Powder: -20°C, 3 years; 4°C, 2 years. In solvent: -80°C, 2 years; -20°C, 1 year. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Biological Activity
IC50 & Target
IC50: 40.3 nM (Wnt responsive STF16 luciferase)[1]
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | ≥ 29 mg/mL (77.24 mM) | use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 2 years) or -20°C (up to 1 year); avoid repeated freeze-thaw cycles.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline |
|---|---|
| Result | ≥ 2.5 mg/mL (6.66 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.5 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL. |
Data provided by the manufacturer.
In Vitro
iCRT 14 can interfere with TCF binding to DNA, beyond its ability to influence the TCF-β-cat interaction[1]. In BT-549 cells, iCRT 14 (10, 25, 50 μM) effectively inhibits cell proliferation in a dose- and time-dependent manner, though it is less potent than iCRT 3[2].
In Vivo
In HCT116 xenografts, iCRT 14 (50 mg/kg, i.p.) markedly lowers CycD1 and tumor proliferation[1].
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Cell Assay[2]
Seed cells at 20,000 cells/well in 96-well plates and incubate overnight. Treat cells with DMSO or one of the Wnt inhibitors (iCRT-3 at 75 μM, iCRT-5 at 200 μM, iCRT-14 at 50 μM, IWP-4 at 5 μM, XAV-939 at 10 μM) for 48 hours. Determine cell viability with the Cell Titer-Glo luminescent cell viability assay kit, reading luminescence on a FLUOstar microplate reader. Run all treatments in triplicate and repeat each experiment three times.
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
Wnt signaling induces radioresistance through upregulating HMGB1 in esophageal squamous cell carcinoma. Cell Death Dis 2018 Apr 1;9(4):433.
SERPINE2 promotes esophageal squamous cell carcinoma metastasis by activating BMP4. Cancer Lett 2020 Jan 28:469:390-398.
Establishing stable and highly osteogenic hiPSC-derived MSCs for 3D-printed bone graft through microenvironment modulation by CHIR99021-treated osteocytes. Mater Today Bio 2024 Jun 1:26:101111. PMID: 38933413
Blockers of Wnt3a, Wnt10a, or β-Catenin Prevent Chemotherapy-Induced Neuropathic Pain In Vivo. Neurotherapeutics 2021 Jan;18(1):601-614. PMID: 33128175
Sustained release of a highly specific GSK3β inhibitor SB216763 in the PCL scaffold creates an osteogenic niche for osteogenesis, anti-adipogenesis, and potential angiogenesis. Front Bioeng Biotechnol 2023 Jul 28:11:1215233. PMID: 37576993
The Osteocyte with SB216763-Activated Canonical Wnt Signaling Constructs a Multifunctional 4D Intelligent Osteogenic Module. Biomolecules 2024 Mar 15;14(3):354. PMID: 38540772
Wnt3a Facilitates SARS-CoV-2 Pseudovirus Entry into Cells. Int J Mol Sci 2023 Dec 22;25(1):217. PMID: 38203386
NDRG3 regulates imatinib resistance by promoting β‑catenin accumulation in the nucleus in chronic myelogenous leukemia. Oncol Rep 2023 Aug;50(2):152. PMID: 37350410
iScience. 2025 Dec 19.
Axin1 regulates tooth root development by inhibiting AKT1-mTORC1 activation and Shh translation in Hertwig's epithelial root sheath. Development 2024 Nov 1;151(21):dev202899. PMID: 39344774
